Clinical Value of ABCB1 and PAI-1 Gene Polymorphisms in Predicting Glucocorticoid-induced Adverse Reactions in Nephrotic Syndrome Patients

Abstract

Objective

Glucocorticoid (GC)-induced adverse reactions (ARs) have been extensively studied due to their potential impact on patients’ health. This study aimed to examine the potential correlation between two polymorphisms [adenosine triphosphate-binding cassette B1 (ABCB1) C3435T and plasminogen activator inhibitor-1 (PAI-1) 4G/5G] and various GC-induced ARs in nephrotic syndrome (NS) patients.

Methods

In this study, 513 NS patients who underwent GC treatment were enrolled. Then, the patients were divided into two groups based on ABCB1 C3435T and PAI-1 4G/5G genotyping, and intergroup comparisons of clinicopathological data and GC-induced ARs were performed. Univariate and multivariate logistic analyses were subsequently conducted to identify potential risk factors for GC-induced ARs, and a nomogram was subsequently established and validated via the area under the ROC curve (AUC), calibration curve and decision curve analysis (DCA).

Results

We identified ABCB1 C3435T as an independent risk factor for the development of steroid-associated avascular necrosis of the femoral head (SANFH) (OR: 2.191, 95% CI: 1.258–3.813, P=0.006) but not as a risk factor for the occurrence of steroid diabetes mellitus (S-DM). On the other hand, PAI-1 4G/5G was identified as an independent risk factor for the development of both SANFH (OR: 2.198, 95% CI: 1.267–3.812, P=0.005) and S-DM (OR: 2.080, 95% CI: 1.166–3.711, P=0.013). Notably, no significant correlation was found between the two gene polymorphisms and other GC-induced ARs. In addition, two nomograms were established and validated to demonstrate strong calibration capability and clinical utility.

Conclusion

Assessing ABCB1 C3435T and PAI-1 4G/5G before steroid treatment in NS patients could be useful for identifying patients at a high risk of developing SANFH and S-DM.

References

[1] Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med, 2005, 353(16): 1711-1723

[2] Tarshish P, Tobin JN, Bernstein J, et al.. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the international study of kidney disease in children. J Am Soc Nephrol, 1997, 8(5): 769-776

[3] Kubo T, Fujioka M, Yamazoe S, et al.. Relationship between steroid dosage and osteonecrosis of the femoral head after renal transplantation as measured by magnetic resonance imaging. Transplant Proc, 1998, 30(7): 3039-3040

[4] Bodor M, Kelly EJ, Ho RJ. Characterization of the human MDR1 gene. AAPS J, 2005, 7(1): E1-E5

[5] Karssen AM, Meijer OC, van der Sandt IC, et al.. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol, 2002, 175(1): 251-260

[6] Breier A, Barancík M, Sulová Z, et al.. P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets, 2005, 5(6): 457-468

[7] Hoffmeyer S, Burk O, von Richter O, et al.. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 2000, 97(7): 3473-3478

[8] Kim RB, Leake BF, Choo EF, et al.. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 2001, 70(2): 189-199

[9] Ichimura A, Matsumoto S, Suzuki S, et al.. A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration. Arterioscler Thromb Vasc Biol, 2013, 33(5): 935-942

[10] Li L, Nie W, Zhou H, et al.. Association between plasminogen activator inhibitor-1-675 4G/5G polymorphism and sepsis: a meta-analysis. PLoS One, 2013, 8(1): e54883

[11] Yang XY, Xu DH. MDR1(ABCB1) gene polymorphisms associated with steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus. Pharmazie, 2007, 62(12): 930-932

[12] French D, Hamilton LH, Mattano LA Jr, et al.. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood, 2008, 111(9): 4496-4499

[13] Kuribayashi M, Fujioka M, Takahashi KA, et al.. Combination analysis of three polymorphisms for predicting the risk for steroid-induced osteonecrosis of the femoral head. J Orthop Sci, 2008, 13(4): 297-303

[14] Rovin BH, Adler SG, Barratt J, et al.. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int, 2021, 100(4): 753-779

[15] Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab, 2006, 32(5): 539-546 Pt 2

[16] Tan B, Li W, Zeng P, et al.. Epidemiological Study Based on China Osteonecrosis of the Femoral Head Database. Orthop Surg, 2021, 13(1): 153-160

[17] Han N, Yan Z, Guo CA, et al.. Effects of p-glycoprotein on steroid-induced osteonecrosis of the femoral head. Calcif Tissue Int, 2010, 87(3): 246-253

[18] Hoffmeyer S, Burk O, von Richter O, et al.. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 2000, 97(7): 3473-3478

[19] Asano T, Takahashi KA, Fujioka M, et al.. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics, 2003, 13(11): 675-682

[20] He W, Li K. Incidence of genetic polymorphisms involved in lipid metabolism among Chinese patients with osteonecrosis of the femoral head. Acta Orthop, 2009, 80(3): 325-329

[21] Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction?. Drug Metab Pharmacokinet, 2005, 20(6): 391-414

[22] Chen JY, Ou RF, Zheng XD. Association of ABCB1 gene polymorphism with glucocorticoid-induced osteonecrosis of femoral head. Chin J Nosocomiol, 2022, 32(17): 2667-2670

[23] Zhu C, Gong CY, Jiang L, et al.. Genetic Polymorphism for Steroid-induced Osteonecrosis of the Femoral Head: A Meta-analysis. Chin J Mod Appl Pharm, 2019, 36(19): 2436-2444

[24] Martínez-Calatrava MJ, Martínez-Larrad MT, Zabena C, et al.. The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population. Diabetes Obes Metab, 2007, 9(1): 134-135

[25] Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res, 2001,(386):19–33

[26] Ferrari P, Schroeder V, Anderson S, et al.. Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation, 2002, 74(8): 1147-1152

[27] Glueck CJ, Fontaine RN, Gruppo R, et al. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res, 1999,(366):133–146

[28] Asano T, Takahashi KA, Fujioka M, et al.. Relationship between postrenal transplant osteonecrosis of the femoral head and gene polymorphisms related to the coagulation and fibrinolytic systems in Japanese subjects. Transplantation, 2004, 77(2): 220-225

[29] Sobhan MR, Mahdinezhad-Yazdi M, Moghimi M, et al.. Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Contributes to Osteonecrosis of the Femoral Head Susceptibility: Evidence from a Systematic Review and Meta-analysis. Arch Bone Jt Surg, 2018, 6(6): 468-477

[30] Clark MG, Wallis MG, Barrett EJ, et al.. Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab, 2003, 284(2): E241-E258

[31] Baron AD. Cardiovascular actions of insulin in humans. Implications for insulin sensitivity and vascular tone. Baillieres Clin Endocrinol Metab, 1993, 7(4): 961-987

[32] Bonadonna RC, Saccomani MP, Del Prato S, et al.. Role of tissue-specific blood flow and tissue recruitment in insulinmediated glucose uptake of human skeletal muscle. Circulation, 1998, 98(3): 234-241

[33] Serné EH, Ijzerman RG, Gans RO, et al.. Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes, 2002, 51(5): 1515-1522

[34] Miles PD, Levisetti M, Reichart D, et al.. Kinetics of insulin action in vivo. Identification of rate-limiting steps. Diabetes, 1995, 44(8): 947-953

[35] Meigs JB, O’donnell CJ, Tofler GH, et al.. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes, 2006, 55(2): 530-537

[36] Tamura Y, Kawao N, Yano M, et al.. Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice. Diabetes, 2015, 64(6): 2194-2206